These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12970317)

  • 1. Dysadherin: expression and clinical significance in thyroid carcinoma.
    Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.
    Batistatou A; Charalabopoulos K; Nakanishi Y; Vagianos C; Hirohashi S; Agnantis NJ; Scopa CD
    Endocr Pathol; 2008; 19(3):197-202. PubMed ID: 18677652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
    Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y
    Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of dysadherin expression in gastric cancer patients.
    Shimada Y; Yamasaki S; Hashimoto Y; Ito T; Kawamura J; Soma T; Ino Y; Nakanishi Y; Sakamoto M; Hirohashi S; Imamura M
    Clin Cancer Res; 2004 Apr; 10(8):2818-23. PubMed ID: 15102690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
    Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
    Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.
    Scheumman GF; Hoang-Vu C; Cetin Y; Gimm O; Behrends J; von Wasielewski R; Georgii A; Birchmeier W; von Zur Mühlen A; Dralle H
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2168-72. PubMed ID: 7608273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
    Ono K; Uramoto H; Hanagiri T
    Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
    Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
    Tsuiji H; Takasaki S; Sakamoto M; Irimura T; Hirohashi S
    Glycobiology; 2003 Jul; 13(7):521-7. PubMed ID: 12672699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
    Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M
    Oncology; 2004; 67(1):73-80. PubMed ID: 15459499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
    Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
    Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin: a differentiation marker in thyroid malignancies.
    Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M
    Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis.
    Ino Y; Gotoh M; Sakamoto M; Tsukagoshi K; Hirohashi S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):365-70. PubMed ID: 11756660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
    Kyzas PA; Stefanou D; Batistatou A; Agnantis NJ; Nakanishi Y; Hirohashi S; Charalabopoulos K
    Am J Surg Pathol; 2006 Feb; 30(2):185-93. PubMed ID: 16434892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of E-cadherin expression in thyroid neoplasms.
    Naito A; Iwase H; Kuzushima T; Nakamura T; Kobayashi S
    J Surg Oncol; 2001 Mar; 76(3):176-80. PubMed ID: 11276021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
    Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
    Batistatou A; Peschos D; Tsanou H; Charalabopoulos A; Nakanishi Y; Hirohashi S; Agnantis NJ; Charalabopoulos K
    Br J Cancer; 2007 May; 96(9):1404-8. PubMed ID: 17437014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
    Aoki S; Shimamura T; Shibata T; Nakanishi Y; Moriya Y; Sato Y; Kitajima M; Sakamoto M; Hirohashi S
    Br J Cancer; 2003 Mar; 88(5):726-32. PubMed ID: 12618882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features.
    Knoll MR; Schwab M; Oestreich K; Rumstadt B; Hagmüller E
    J Exp Clin Cancer Res; 1997 Jun; 16(2):177-82. PubMed ID: 9261744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.